Hartford, Christopher A. http://orcid.org/0000-0001-7095-0106
Sherman, Steven A.
Karantzoulis, Stella
Guillemin, Isabelle
Phinney, Michael G.
Kelly, Kimberly L.
Negron, Kayla E.
Raja, Shruti M.
Rofail, Diana
Funding for this research was provided by:
Regeneron Pharmaceuticals
Article History
Received: 17 July 2023
Accepted: 5 September 2023
First Online: 25 September 2023
Declarations
:
: Christopher Hartford, Steven Sherman, and Diana Rofail are all employees of and stockholders in Regeneron Pharmaceuticals, Inc. Stella Karantzoulis, Isabelle Guillemin, Michael Phinney, Kimberly Kelly, and Kayla Negron were all employees of IQVIA at the time of study conduct. Shruti Raja is a consultant to Regeneron Pharmaceuticals, Inc. The authors received no honoraria related to the development of this publication.
: The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and are consistent with Good Clinical Practice and applicable regulatory requirements. The study was reviewed and approved by the WCG institutional review board (IRB), IRB number 20213567. The research protocol, interview guides, all documents associated with patient interviews, and all clinician communication documents were also reviewed and approved by WCG IRB. Informed, written consent was obtained electronically from each participant prior to their enrollment.